These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27926949)

  • 41. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.
    Walsh SL; Babalonis S
    Curr Top Behav Neurosci; 2017; 34():33-58. PubMed ID: 27356522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.
    Mendelson J; Flower K; Pletcher MJ; Galloway GP
    Exp Clin Psychopharmacol; 2008 Oct; 16(5):435-41. PubMed ID: 18837640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New drug buprenorphine can treat patients addicted to heroin or prescription pain medications.
    Clark HW
    W V Med J; 2003; 99(1):42. PubMed ID: 12762216
    [No Abstract]   [Full Text] [Related]  

  • 45. Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.
    Browne CA; Erickson RL; Blendy JA; Lucki I
    Neuropharmacology; 2017 May; 117():401-407. PubMed ID: 28188737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 47. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.
    Meader N
    Drug Alcohol Depend; 2010 Apr; 108(1-2):110-4. PubMed ID: 20074867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of kappa opioid receptors in developing rat brain - Implications for perinatal buprenorphine exposure.
    Tan KZ; Cunningham AM; Joshi A; Oei JL; Ward MC
    Reprod Toxicol; 2018 Jun; 78():81-89. PubMed ID: 29635048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?
    Costa E Silva JA
    Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 52. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient.
    Book SW; Myrick H; Malcolm R; Strain EC
    Am J Psychiatry; 2007 Jun; 164(6):979. PubMed ID: 17541066
    [No Abstract]   [Full Text] [Related]  

  • 53. Buprenorphine: considerations for pain management.
    Johnson RE; Fudala PJ; Payne R
    J Pain Symptom Manage; 2005 Mar; 29(3):297-326. PubMed ID: 15781180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
    Yu G; Yue YJ; Cui MX; Gong ZH
    J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine-containing treatments: place in the management of opioid addiction.
    Robinson SE
    CNS Drugs; 2006; 20(9):697-712. PubMed ID: 16953647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
    Sullivan JG; Webster L
    Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research.
    Li JX
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10225-7. PubMed ID: 27573851
    [No Abstract]   [Full Text] [Related]  

  • 58. Buprenorphine in acute pain: a partial agonist or not?
    Holyoak R; Vlok R; Melhuish T; Thang C; White L
    Br J Anaesth; 2019 Oct; 123(4):e484-e485. PubMed ID: 31351591
    [No Abstract]   [Full Text] [Related]  

  • 59. Patient and Public Safety Maximized by Rapid Opioid Taper-Reply.
    Guillod P; Edens EL; Becker WC
    JAMA Intern Med; 2017 Jun; 177(6):896. PubMed ID: 28586812
    [No Abstract]   [Full Text] [Related]  

  • 60. Opioid analgesics pass the acid test.
    Navratilova E; Patwardhan A; Porreca F
    Lancet; 2019 Apr; 393(10181):1579-1581. PubMed ID: 31007186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.